When a child has Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disease, families and doctors search for anything that might help preserve strength and mobility. A recent study followed 66 boys with DMD for 48 weeks to see if adding a daily dose of tamoxifen—a drug used for other conditions—to their standard steroid treatment could make a difference. The core finding was straightforward: there was no significant difference in motor function between boys who started tamoxifen early versus those who started it later. The researchers also found no evidence of a 'sustained effect' from the drug, meaning its use did not seem to slow the disease's progression over time.
It's important to understand what this study was and wasn't. This was an 'open-label extension' study, meaning everyone involved knew they were getting tamoxifen. This type of study is not as rigorous as a blinded trial where no one knows who is getting the real drug versus a placebo, so it's harder to draw firm conclusions about cause and effect. On the safety side, the report notes that tamoxifen was 'well tolerated overall' during the study period, with no deaths or life-threatening serious events reported among the participants.
The researchers themselves state they 'cannot provide statistical nor clinical evidence' that prolonged tamoxifen treatment is effective in delaying DMD progression. For now, this particular approach of adding tamoxifen to corticosteroids does not appear to be a promising path forward for treating the muscle weakness in DMD. The search for effective therapies continues.